Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price traded up 9.6% on Friday . The company traded as high as $63.90 and last traded at $64.39. 513,044 shares traded hands during mid-day trading, a decline of 23% from the average session volume of 663,138 shares. The stock had previously closed at $58.77.
Wall Street Analysts Forecast Growth
TARS has been the topic of several recent analyst reports. Zacks Research raised shares of Tarsus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, September 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a report on Saturday, September 27th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $66.67.
Read Our Latest Report on TARS
Tarsus Pharmaceuticals Trading Up 10.9%
The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.21 and a current ratio of 5.26. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -27.97 and a beta of 0.81. The business has a fifty day moving average price of $52.98 and a 200 day moving average price of $47.61.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.15). The firm had revenue of $102.66 million for the quarter, compared to analysts' expectations of $95.81 million. Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. As a group, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.
Insider Buying and Selling
In other news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total value of $332,220.00. Following the completion of the sale, the chief executive officer owned 812,106 shares in the company, valued at $44,966,309.22. This represents a 0.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director William J. Phd Link sold 27,116 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the sale, the director directly owned 143,332 shares of the company's stock, valued at $8,169,924. This represents a 15.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 39,116 shares of company stock valued at $2,177,832. Company insiders own 8.97% of the company's stock.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. Amalgamated Bank boosted its holdings in shares of Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company's stock worth $66,000 after acquiring an additional 339 shares in the last quarter. Osaic Holdings Inc. boosted its position in Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company's stock valued at $113,000 after purchasing an additional 2,462 shares during the last quarter. Quarry LP grew its stake in Tarsus Pharmaceuticals by 20.0% in the first quarter. Quarry LP now owns 3,599 shares of the company's stock valued at $185,000 after purchasing an additional 599 shares in the last quarter. Finally, AlphaQuest LLC acquired a new position in Tarsus Pharmaceuticals in the 1st quarter worth about $189,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
